Psychedelic-Induced Personality Changes: Evidence and Gaps (Global, 2014–2024)

Psychedelics and Personality: Systematic Review Finds Consistent Trait Shifts

A systematic review published in October 2026 synthesizes a decade of research, finding that psychedelic compounds—including psilocybin, LSD (lysergic acid diethylamide), and ayahuasca—are consistently associated with reductions in neuroticism and other personality trait changes. The review, which drew from 27 studies and 1,941 participants across Web of Science, PubMed, Scopus, and ClinicalTrials.gov, highlights a growing body of evidence linking psychedelic use to shifts in personality traits that may underpin improvements in mental health.

Most studies included in the review report that reductions in neuroticism—a personality dimension associated with emotional instability and vulnerability to stress—are the most robust and consistent finding. Some studies also note increases in openness and extraversion, though results are more variable. Notably, the review found that the magnitude and direction of personality change may depend on baseline characteristics and the subjective quality of the psychedelic experience, suggesting individual differences play a significant role in outcomes.

Mechanisms and Context: How Psychedelics May Influence Personality

Psychedelics are hypothesized to induce personality changes by disrupting entrenched patterns of thought and emotion, potentially via neuroplasticity and altered connectivity in brain networks such as the default mode network (DMN). The review notes that acute psychedelic experiences—often described as "mystical" or "insightful"—may catalyze lasting changes in self-perception and emotional processing, which can translate into measurable shifts on standardized personality inventories.

However, the evidence base remains limited by methodological heterogeneity. Most studies are small (median n < 100), with variable designs ranging from open-label observational studies to a handful of randomized controlled trials (RCTs). Only a minority of studies included psychedelic-naïve participants, making it difficult to disentangle the effects of prior drug exposure, expectancy, and self-selection. Furthermore, the review highlights that follow-up periods are often short (weeks to months), leaving the durability of personality changes uncertain.

Implications for Clinical Trials and Policy

The findings of this review have concrete implications for the design of future clinical trials and for regulatory perspectives on psychedelic-assisted therapy. Regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) increasingly require evidence not only of symptom reduction but also of broader functional and psychological outcomes, including personality and quality of life measures. This review suggests that personality trait change could be a meaningful secondary endpoint in psychedelic trials, especially for conditions like depression and anxiety where neuroticism is a known risk factor.

For trial designers, the review underscores the importance of including psychedelic-naïve participants and employing rigorous, double-blind, placebo-controlled methodologies. It also points to the value of long-term follow-up (12 months or more) to assess the persistence and clinical significance of personality changes. As a non-obvious implication, the review suggests that pre-screening for baseline personality traits may help identify individuals most likely to benefit from psychedelic interventions—a decision criterion not widely used in current protocols.

Risks, Unknowns, and Research Gaps

Despite promising signals, the review emphasizes that the current evidence is insufficient to draw definitive conclusions about the safety, efficacy, and generalizability of psychedelic-induced personality change. Potential risks include the possibility of maladaptive changes in personality (e.g., increased impulsivity or openness leading to risky behaviors), as well as the ethical and philosophical implications of intentionally altering core aspects of selfhood. The review also notes that most studies have not adequately controlled for expectancy effects, therapist influence, or cultural context—all factors that could confound results.

Another critical gap is the lack of data on diverse populations. Most participants in the reviewed studies were White, middle-class, and highly educated, raising questions about generalizability to broader clinical and community settings. The review calls for larger, multisite trials with diverse samples and standardized protocols to address these limitations.

Looking Ahead: The Path to Clarity

The next phase of psychedelic research will require well-powered, methodologically rigorous studies to clarify the mechanisms, durability, and clinical relevance of personality trait changes. As regulatory and clinical interest in psychedelics grows, integrating personality assessment into trial design may offer new insights into who benefits most—and why. Importantly, future studies should prioritize psychedelic-naïve participants, long-term follow-up, and diverse recruitment to build a more robust and generalizable evidence base.

For now, while early findings are encouraging, clinicians and policymakers should remain cautious. The field must balance optimism about therapeutic potential with a clear-eyed appraisal of the risks, unknowns, and ethical complexities inherent in altering personality traits through pharmacological means.

How we research: This analysis was written by Dr. Alex J. Harper, PhD (Neuroscience, University of Cambridge), and reviewed by Dr. Maria L. Chen, MD (Psychiatry) on 2026-10-15. Primary sources include the systematic review at OpenAlex W7221635549 and ClinicalTrials.gov trial records.